dr. mesa on jakarta-2 reanalysis for myelofibrosis
Published 5 years ago • 111 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
0:57
dr. mesa on challenges in myelofibrosis treatment
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
1:16
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:11
dr. mesa on the utility of fedratinib for patients with myelofibrosis who progress on ruxolitinib
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
2:41
jakarta & jakarta2: pfs and os with fedratinib in myelofibrosis
-
2:22
dr. mesa on the evolving role of jak2 inhibitors in myelofibrosis
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:54
dr. mesa discusses jak inhibitors for myelofibrosis
-
1:48
dr. mesa on pacritinib for myelofibrosis
-
4:46
fedratinib for primary myelofibrosis
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
1:27
jakarta and jakarta2: os and pfs analysis of fedratinib in myelofibrosis
-
5:10
fedratinib in mf: jakarta2 and freedom trials
-
0:59
dr. michaelis on fedratinib in myelofibrosis treatment
-
2:34
dr. mesa on ruxolitinib in myelofibrosis